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One of the main objectives in systems biology is to understand the biological mechanisms
that give rise to the phenotype of a microorganism by using high-throughput technologies
(HTs) and genome-scale mathematical modeling. The computational modeling of
genome-scale metabolic reconstructions is one systemic and quantitative strategy for
characterizing the metabolic phenotype associated with human diseases and potentially
for designing drugs with optimal clinical effects. The purpose of this short review is to
describe how computational modeling, including the specific case of constraint-based
modeling, can be used to explore, characterize, and predict the metabolic capacities
that distinguish the metabolic phenotype of cancer cell lines. As we show herein, this
computational framework is far from a pure theoretical description, and to ensure proper
biological interpretation, it is necessary to integrate high-throughput data and generate
predictions for later experimental assessment. Hence, genome-scale modeling serves as
a platform for the following: (1) the integration of data from HTs, (2) the assessment of
how metabolic activity is related to phenotype in cancer cell lines, and (3) the design
of new experiments to evaluate the outcomes of the in silico analysis. By combining the
functions described above, we show that computational modeling is a useful methodology
to construct an integrative, systemic, and quantitative scheme for understanding the
metabolic profiles of cancer cell lines, a first step to determine the metabolic mechanism
by which cancer cells maintain and support their malignant phenotype in human tissues.
Keywords: computational modeling of metabolism, cancer metabolic phenotype, constraint-based modeling,
genome scale metabolic reconstruction, high throughput biology
INTRODUCTION
Cancer is a complex disease that is characterized by uncontrolled
cell growth. At the genetic level, cancer research has focused pri-
marily on identifying oncogenes and tumor suppressors that ini-
tiate and promote the cancer phenotype (Bishop and Weinberg,
1996). Thus, the loss or gain of function in tumor suppressors
or oncogenes induces changes in the regulatory mechanisms that
control key processes associated with carcinogenesis, such as cell
transformation, proliferation, invasion, intravasation, and metas-
tasis (Thiery, 2002). Notably, several processes associated with the
progress of this disease have been identified as the hallmarks of
cancer. Currently, these hallmarks are sustained proliferative sig-
naling, the evasion of growth suppressors, resistance to cell death,
the induction of angiogenesis, the activation of invasion and
metastasis, replicative immortality, tumor-promoting inflamma-
tion and the reprogramming of energymetabolism (Hanahan and
Weinberg, 2011). With the recent advances in metabolome tech-
nology, there is now great interest in elucidating how metabolic
profiles change to meet the metabolic demand during carcino-
genesis. One of the most clear lines of evidence supporting these
metabolic alterations in cancer cells is that cancer cells prefer-
entially use glycolysis instead of aerobic respiration to obtain
ATP even under aerobic conditions; this finding is known as
the Warburg effect (Ward and Thompson, 2012). From an ener-
getic point of view, glycolysis is a less efficient mechanism to
produce ATP compared with oxidative phosphorylation (2 ATP
molecules and 36 ATP molecules, respectively, produced from 1
molecule of glucose). Given the much higher efficiency of oxida-
tive phosphorylation, a question arises: what is the metabolic
advantage of using glycolysis to sustain the uncontrolled prolif-
eration of cancer cells. To explain this apparent contradiction,
Warburg proposed that cancer cells do not have functional mito-
chondria (Warburg, 1956); however, contrary to this hypothesis,
there is evidence that the oxidative phosphorylation pathway is
active in some human cancer cells (Weinhouse, 1976). Hence,
the central question still requires an answer. To this end, there
have been many hypotheses to explain this metabolic prefer-
ence, for example, the hypothesis that the use of glycolysis is an
effect of oxygen deprivation in the tumor. Oxygen deprivation is
observed in some areas of solid tumors, and as a consequence,
there could be reduced dependence of energetic metabolism on
aerobic respiration (Braun et al., 2001). Furthermore, there is evi-
dence that the prolonged exposure of cells to hypoxia promotes
activity that favors the cancer phenotype, including the activa-
tion of hypoxia-inducible factor (HIF-1α), which is an important
regulator of the metabolic activity of glycolysis and the glucose
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uptake rate (Robey et al., 2005; Brahimi-Horn et al., 2007).
However, even though the activation of HIF-1α may be a rea-
sonable explanation, HIF-1α has been shown to be expressed in
tumor cells even in the presence of oxygen (pseudo-hypoxia),
and therefore, this piece of the puzzle remains unsolved (King
et al., 2006). In our opinion, finding the answer requires the com-
bined use of high-throughput experiments and computational
models able to determine which metabolic pathways are neces-
sary to support the cancer phenotype and how these pathways
are organized to support aerobic glycolysis during cancer cell
proliferation. The understanding of such a phenomenon is cru-
cial to the development of systematic schemes that contribute to
identifying mechanisms that may reverse or delay the develop-
ment of a malignant state. To contribute to this field of research,
we present and discuss a computational analysis of the central
metabolic pathway in cancer cell lines. This formalism—based
on constraint-based modeling—allows us to (1) integrate high-
throughput data, (2) generate biological hypothesis regarding
the crucial pathways involved in cancer, and (3) design experi-
ments to evaluate the in silico predictions. By analyzing specific
examples, we provide evidence that this formalism can serve as a
rational guide for identifying enzymatic targets with the potential
to inhibit the cancer phenotype.
HIGH-THROUGHPUT TECHNOLOGY: TOP–DOWN
DESCRIPTION
Integrative approaches in systems biology can be used to orga-
nize and interpret experimental data and to provide a greater
understanding of the metabolic principles that underlie the can-
cer phenotype. To this end, high-throughput technologies (HTs)
are a valuable tool to characterize the global activity of living
organisms through the analysis of massive amounts of data on
gene expression, protein concentrations, or metabolic profiles, to
name a few examples. Importantly, the profiles obtained from
these data constitute a way to characterize the phenotype of a
microorganism through qualitative and quantitative procedures,
both of which are important tools to assess the results obtained
from computational models.
Overall, these technologies have contributed to the under-
standing of some mechanisms that trigger the cancer phenotype
at diverse biological levels, and currently, there is an overwhelm-
ing number of genes, proteins, and metabolites whose activities
are known to be associated with the evolution of this disease. For
instance, Kreig et al. demonstrated in 2004 that alterations at the
subunit level of a single enzyme complex (cytochrome c oxidase)
are correlated with altered metabolism in tumors (Krieg et al.,
2004).
In 2009, Sreekumar et al. reported the profiles of more than
1126 metabolites across 262 clinical samples related to prostate
cancer. These unbiased metabolome profiles were able to distin-
guish benign clinically localized prostate cancer and metastatic
disease (Sreekumar et al., 2009). Furthermore, Fan et al. stud-
ied the metabolic perturbations arising from malignant trans-
formation in human lung cancers in situ (Fan et al., 2009).
They investigated these metabolic changes by infusing uniformly
labeled 13C-glucose into human lung cancer patients, followed
by resecting and processing paired non-cancerous lung tissues
and non-small cell carcinoma tissues, as well as blood plasma.
Complementary, in 2010, Bottomly et al. used massively paral-
lel sequencing (ChIP-seq) to provide evidence that the Wnt/β-
catenin and mitogen signaling pathways intersect directly to
regulate a defined set of target genes in colon cancer (Bottomly
et al., 2010). Equally important, in 2010, Huarte and Rinn,
using ChIP-seq, provided data that improved the understand-
ing of the role that large ncRNAs have in cancer pathways
(Huarte and Rinn, 2010). Large ncRNAs are also emerging as
important regulatory molecules in tumor-suppressor and onco-
genic pathways. Notably, the metabolic pathways associated with
the cancer phenotype have been studied using these and others
methods, and the potential control of metabolism has opened up
an alternative avenue for designing novel therapeutic approaches
in cancer treatment (Godinot et al., 2007). In 2009, Vanableset
et al. published a study in which microarrays were used to show
that approximately half of all active alternative splicing events in
ovarian and breast tissues were altered in tumors, and many of
these events seem to be regulated by the binding of a single fac-
tor: the RNA binding protein FOX2 (Venables et al., 2009). As we
said before, there is an overwhelming number of examples show-
ing the use of HTs to provide a greater understanding of cancer
phenotype, but an extensive discussion of these achievements falls
outside to the purpose of this review.
In light of these and other findings reported in the literature,
carcinogenesis can be characterized as a particular metabolic phe-
notype in an organism that results from anomalous interactions
among many biological components (genes, proteins, ncRNA,
metabolites, etc.); in other words, carcinogenesis can be charac-
terized as a dysfunctional state of a biological network. Thus, to
understand the biochemical mechanisms that sustain cancer, it
makes sense to study this disease in a collective way, i.e., as a result
of interacting networks. At this stage, there are some issues that
must be addressed; for instance, once we have experimental data
regarding gene expression or the proteome, how do we handle
these data and construct a coherent history of the metabolic activ-
ity associated with the cancer phenotype in a microorganism.
Which metabolic pathways have a central role in cancer and how
can these pathways be used to identify potential targets for clinical
treatment. Despite the enormous contribution of HTs to the
identification of the genetic and metabolic mechanisms that favor
the development of cancer, most of these top-down schemes are
descriptive and non-predictive. Thus, to move toward a quanti-
tative and predictive scheme, the use of computational modeling
for genome-scale metabolic reconstruction is necessary. In this
context, there are different schemes for the computational mod-
eling of metabolic pathways, but herein we focus on Flux Balance
Analysis (FBA), a paradigm in systems biology whose utility to
understand and predict metabolic states has been proven in a
variety of microorganisms (Resendis-Antonio et al., 2007, 2010,
2011, 2012; Orth et al., 2010; Schellenberger et al., 2011; Benedict
et al., 2012; Kim and Reed, 2012; Martinez et al., 2012; Paglia
et al., 2012; Pardelha et al., 2012; Tilghman et al., 2012).
FLUX BALANCE ANALYSIS
Constraint-based modeling is a successful framework in systems
biology that has proven useful to explore the metabolic activity
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in microorganisms and whose principles and methods can
be reviewed elsewhere. Among the computational methods
classified in this framework, FBA constitutes a fundamen-
tal tool for integrating high-throughput data and assessing
predictions regarding genotype–phenotype relationships
(Orth et al., 2010; Schellenberger et al., 2011). Briefly, having
selected the metabolic reconstruction of a microorganism, FBA
lets us identify the space spanned by feasible metabolic capacities
for the organism under steady state conditions by imposing
thermodynamic, enzymatic, and regulatory constraints. This
space contains an overwhelming number of metabolic states, and
in turn each state represents different strategies that balance the
metabolic requirements of the cell and the nutrients available
in the environment. Importantly, not all these states produce
equivalent metabolic phenotypes, for instance, an equivalent
level of biomass production, because some states are more
efficient than others. Thus, having selected a specific biological
objective, for instance, biomass production, the problem in FBA
is reduced to finding the metabolic state, or states, that maximize
or minimize that phenotype. The elucidation of the metabolic
state associated with a specific physiological situation requires
two steps: (1) the reconstruction of an objective function (OF)
that represents a biological process, which, for instance can be
biomass production or the production of a specific metabolite;
and (2) the identification of a metabolic state that maximizes or
minimizes this state by an OF. A FBA workflow with the required
data and methodologies is shown in Figure 1 and Appendix.
Understanding the metabolic alterations that distinguish cancer
cells from normal cells requires systemic and systematic schemes
to uncover the mechanisms that support the cancer phenotype,
and this understanding will facilitate the design of more effective
treatments. In the remainder of this short review, we will specially
focus on how FBA can be a useful tool for this latter purpose.
Thus, the purpose of this paper is to show how in silico analysis
can serve as a guide for modeling and exploring the metabolic
consequences of the Warburg effect, the implications of this
effect regarding the cancer phenotype and how genome-scale
modeling can be used to identify enzymatic targets with potential
therapeutic applications (Resendis-Antonio et al., 2010).
MODELING CANCER METABOLISM
As we described above, the Warburg effect is a fundamental
metabolic process that contributes to the malignant transforma-
tion of most cancer cells. The fundamental nature of this effect
makes it attractive to study, and consequently, the understanding
of this effect could have conceptual and practical implications for
new clinical treatments. With this aim in mind, in this section, we
will briefly discuss how constraint-based modeling can be used
as a computational tool to characterize the metabolic activity
of cancer cells during aerobic glycolysis. Furthermore, we will
focus on showing the practical implications of constraint-based
modeling that may interest biomedical researchers in the field
of cancer research. For the sake of simplicity, our results are
constrained to a metabolic reconstruction whose set of reactions
represents the central metabolism in a cell exposed to specific
external conditions (see Figure 2). Although this metabolic
network—containing only 89 reactions and 98 metabolites—is
only a subset of the human metabolic reconstruction, we argue
that it serves as a baseline to exemplify the method and, simul-
taneously, as a benchmark to assess the in silico predictions in
terms of the experimental data currently found in the literature.
In particular, we will show that our method can be used as an
auxiliary computational tool for identifying a set of enzymes
with an important role in supporting the metabolic phenotype in
cancer cells. To explore the metabolic activity in cancer cells using
the perspective of constraint-based modeling, three requirements
should be met systematically: (1) the metabolic reconstruction
of a human cell, (2) the definition of an OF associated with a
physiological state, and (3) the completion of computational
simulations and the experimental assessment of their outputs.
METABOLIC RECONSTRUCTION
Once one has identified the organism of study, the immediate
questions are how to define the physical limits of the system and
how to define the number of metabolic reactions in the network
to be included in the analysis. With the goal of analyzing the
metabolic state associated with the Warburg effect, we assumed
that the following metabolic pathways define our system: glycoly-
sis, the pentose phosphate pathway, the TCA cycle, and oxidative
phosphorylation (see Figure 2). In addition, we considered our
system to be capable of importing glucose and glutamine and
exporting lactate. These properties are in agreement with the fact
that cancer cells have an increased uptake rate of glucose and that
carcinogenesis proceeds in an acidic microenvironment.
In the rest of this work, our discussion will be centered on
a metabolic reconstruction of the central metabolism in human
cells. As we show, this metabolic reconstruction and its com-
putational modeling have two advantages: (1) this model can
demonstrate how to explore the relationship between constraint-
based modeling and phenotype in cancer cell lines, and (2) this
model constitutes a proper framework to explore how the pertur-
bations of some enzymes participating in central metabolism can
affect the cancer phenotype. Clearly, this latter information is nec-
essary to calibrate the model and evaluate the in silico predictions.
However, given that metabolic alterations in cancer cells have
consequences with respect to network organization, there will be
additional pathways—not considered herein—that can play an
important role in driving carcinogenesis. This latter point is an
avenue that should be explored in more detail. Despite this sim-
plification, we show that this first approachmeets the goals of this
paper: to provide evidence that constraint-based modeling is a
coherent framework to analyze themetabolic state associated with
the cancer phenotype and to predict the genotype–phenotype
relationship in cancer cell lines.
BIOMASS PRODUCTION BY CANCER CELLS:
CONSTRUCTION OF A PROPER OBJECTIVE FUNCTION
As we explained in the previous sections, an OF is required to
perform FBA and find the metabolic state associated with spe-
cific environmental conditions. From a phenomenological point
of view, cancer cells exhibit a metabolic alteration that ensures
the biosynthesis of the building blocks required to meet the
demand generated by uncontrolled cell proliferation. To iden-
tify this dysfunctional metabolic state, we constructed an OF by
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FIGURE 1 | Scheme of Flux Balance Analysis (FBA). First is the
definition of the network, HT data is used to complete different levels of
information (either in the network, concentration, or fluxes), the network
get represented in an stoichiometric matrix. Given the fluxes, the
concentration of each metabolite and the stoichiometric matrix the steady
state is found.
selecting those metabolites in our reconstruction that are uti-
lized as precursors for producing amino acids, nucleotides, fatty
acids, electron carriers, and compounds involved in energy trans-
fer. Hence, taking into account this argument, the OF can be
written as:
OF (Biomass) = c1ATP + c2NADH + c3NADPH + c4R5P
+ c5ATP + c6SUCC
where all the coefficients ci, i = 1 . . . 6, represent the weight fac-
tors required to produce one unit of biomass (nmol/gDW· hr−1).
In this context, it is necessary to identify the metabolic profile that
optimizes the OF, and these conditions represent those that yield
the maximal biomass production associated with the prolifera-
tion of cancer cells. It is important to mention that given that
the demand for the production of these metabolites is equally
required during normal cell proliferation, our main hypothesis
to distinguish the metabolic state associated with normal pro-
liferation from the metabolic state associated with cancer is to
assume that this latter state requires a metabolic profile that max-
imizes the OF. In other words, given that the cancer phenotype is
related to uncontrolled cell proliferation, it is a plausible hypoth-
esis that the relationship among the metabolic pathways that
maximizes the production of biomass is closely related to cancer
metabolism.
EXPLORING THE GENOTYPE–PHENOTYPE RELATIONSHIP
IN CANCER METABOLISM
Having defined the uncontrolled cell proliferation in cancer cells
using the OF, we can characterize the feasible space of metabolic
responses using FBA and eventually identify and explore those
metabolic pathways that support the cancer phenotype. Hence,
under this assumption, we can identify the metabolic state or
states that maximize the OF and, in turn, elucidate the entire
metabolic mechanism required to support the cancer phenotype
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FIGURE 2 | Central metabolism in cancer cell lines. LAC represents
lactate, G6P represents glucose-6phosphate, F6P represents fructose 6
phosphate, FDP represents fructose 1,6 biphospate, G3P represents
glyceraldehydes 3 phosphate, 13DPG represents 1,3 biphosoglycerate,
3PG represent 3 phosphoglycerate, 2PG represents 2-phopho glycerate,
PEP represents phosphenol pyruvate, PYR represents pyruvate,
6PGCL represents 6-phosphoglucono-δ-lactone, 6PGC represents
6-phosphogluconate, RU5Prepresents ribulose 5-phosphate, R5P represents
Ribose 5 phosphate, X5P represents Xylulose 5 phosphate, S7P represents
sedoheptulose 7-phosphate, E4P represents erythrose 4-phosphate,
OAA represents oxaloacetate, SUC-COA represents succinyl-CoA, ACCOA
represents acetyl CoA.
(see Figure 3). Some advances have been reported recently in
this type of scheme for studying metabolism in cancer cells.
For instance, it has been reported that the constraint-based
modeling of central metabolism was able to qualitatively repro-
duce an experimental growth curve for the HeLa cancer cell
line (Resendis-Antonio et al., 2010). Notably, this study pro-
vides a computational methodology that contributes to identi-
fying the metabolic reactions whose activities could be crucial
to support the cancer phenotype. This latter issue is a worthy
goal to optimize the design of drugs targeting human cancer
(see Figure 3).
Among the target enzymes identified by this in silico analy-
sis are glucose transporters and several glycolytic enzymes that
are essential for optimizing biomass production enolase (ENO),
glyceraldehyde-3-phosphate dehydrogenase (GAPD), phospho-
glycerate (PGC), pyruvate kinase (PYK), and lactate dehydro-
genase (LDH) (Resendis-Antonio et al., 2010). Consistent with
these results, targeting glucose transporters and the phospho-
rylation steps in glycolytic pathways has been shown to be a
complementary strategy for inhibiting the cancer phenotype
(Gatenby and Gillies, 2004; Xu et al., 2005; Christofk et al.,
2008). For the sake of illustration, in the last part of this article,
we will analyze two specific enzymes identified in this analy-
sis: LDH and pyruvate dehydrogenase. An extensive analysis that
includes other metabolic pathways has been reviewed previously
(Resendis-Antonio et al., 2010). Both enzymes were identified
through constraint-based modeling, and in agreement with this
result, there is experimental evidence suggesting that the control
of the activities of these enzymes can be used as a strategy to reg-
ulate the cancer phenotype (see Figure 3) (Shaw, 2006; Hsu and
Sabatini, 2008).
LDH contributes to the acidification of the microenvironment
and stimulates cancer cell proliferation via the transformation
of pyruvate into lactate in the cytoplasm, which consequently is
exported outside the cell. As Figure 3 shows, simulations with
FBA under low oxygen uptake rates—emulating hypoxia—show
that a decrease in the enzymatic activity of LDH is followed by
a decreased metabolic activity in the form of glycolysis, as well
as decreases in the rates of some reactions in the TCA cycle
and pentose phosphate pathway (Resendis-Antonio et al., 2010).
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FIGURE 3 | Analysis with constraint-based modeling. (A) Having
reconstructed the metabolic network, in silico gene deletion allows to
identify the phenotype behavior in cancer cell lines. In this case, phenotype is
defined in terms of biomass production. Three effects can occur in this
situation: (1) genes whose activity is dispensable, (2) genes whose
expression reduce the biomass, and (3) genes whose activity is essential to
biomass production. Based on in silico analysis, we conclude that lactate
dehydrogenase (LDH) has a pivotal metabolic control on cancer cell growth
(Resendis-Antonio et al., 2010). Supporting this finding, panel (B) shows the
effects that variations on the enzymatic activity of LDH have on some
enzymes participating in glycolysis, TCA cycle and pentose phosphate. As the
figure shows according the metabolic activity of LDH decrease, we note a
reduced activity on all the enzymes integrating these pathways. Regions in
red and blue represent a higher (H) and lower (L) metabolic flux activity,
respectively. (C) Phenotype phase plane considering the activity of pyruvate
dehydrogenase (PDH) and glucose uptake rate.
In the case of glycolysis, this metabolic effect has been observed
experimentally, and the increased rate of lactate production has
been proposed to be a necessary condition for the Warburg effect
(Dang and Semenza, 1999). Even more important for practical
purposes, there is experimental evidence that the inhibition of
LDH reduces the activities of some glycolytic enzymes and con-
sequently can be an alternative mechanism to reduce the growth
rate in cancer cells (Fantin et al., 2006).
On the other hand, constraint-based modeling suggests that
pyruvate dehydrogenase (PDHm) can perform a central role
driving cell proliferation in cancer cell growth (see Figure 3).
Supporting this computational finding, there is evidence that the
metabolic inhibition of PDHm contributes to the Warburg effect,
and in the case of human neck and head squamous carcino-
mas, the inhibition of PDHm enhances the malignant phenotype
(McFate et al., 2008; Jones and Thompson, 2009). This obser-
vation makes sense given that the activation of HIF negatively
regulates the catalytic activity of PDHm through the activation of
pyruvate dehydrogenase kinase 1 (see Resendis-Antonio et al., 2010
and the references therein). Simultaneously, the metabolic pheno-
type of cancer is favored because HIF induces the overproduction
of enzymes that participate in the glycolytic pathway (Dang and
Semenza, 1999). In summary, these in silico studies led us to con-
clude that the combined effect of an increase in aerobic glycolysis
(theWarburg effect) and a decrease in the activity of PDHm seems
to confer a selective advantage for survival and cell proliferation
in cancer cells.
Another interesting question that we can address with
constraint-based modeling is the effect of alterations of two
selected metabolic reactions in the reconstruction on the can-
cer cell phenotype (Varma and Palsson, 1994; Price et al., 2004).
For this purpose, phenotype phase plane (PPP) analysis is a sim-
ple computational procedure to visually explore the value of an
OF as a function of alterations in two selected metabolic fluxes.
For instance, PPP analysis based on the metabolic activity of
PDH and glucose transporters has suggested that an increase in
the glucose uptake rate combined with a decrease in the PDHm
enzymatic activity may increase the growth rate of cancer cell lines
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only inside of certain region of the feasible metabolic space (see
Figure 3). Thus, as one can imagine from these interpretations,
constraint-based modeling contributes to the development of
biological hypotheses and, in turn, the design of experiments to
test these hypotheses.
In light of these results, constraint-based modeling repre-
sents an effort to construct a computational platform that
can serve as a guide for the descriptive and predictive analy-
sis of cancer metabolism involving continuous dialog with the
experimental data.
CONCLUSIONS
Cancer is a multifactorial disease, and the development of effec-
tive clinical treatments requires new paradigms and multidisci-
plinary strategies that systematically integrate (1) physiological
knowledge, (2) experimental data on cell activity obtained using
different HTs, and (3) an integrative description of these data in
terms of computational modeling. In the case of human cancers,
there are a variety of mechanisms by which this dysfunctional
phenotype can be triggered; however, some hallmarks have been
suggested to be independent of the type of cancer, and they are
commonly present in all cancers (Hanahan and Weinberg, 2011).
Among these hallmarks, themetabolic transformation that occurs
during carcinogenesis is a promising marker that can be used to
understand the progression of the disease and its principles and
to potentially move toward optimal schemes in drug design. In
this work, we have demonstrated how a computational model,
based on constraint-based modeling, can be useful to explore
the metabolic profile associated with the cancer phenotype.
Furthermore, we have shown how this formalism can eventually
be useful to identify proteins whose enzymatic activities could be
essential to support the cancer phenotype.
Even though the in silico model involves numerous simplifica-
tions, we argue that this type of scheme can be used to explore
fundamental and practical issues related to cancer in a systematic
and systemic manner. Thus, the in silico identification of lactate
and pyruvate dehydrogenase as two potential enzymes necessary
to support the cancer phenotype exemplifies how constraint-
based modeling in systems biology can be useful to understand
how metabolism participates in carcinogenesis and, eventually,
how such modeling could be used in the design of experimen-
tal strategies to limit or delay the progression of the disease.
In this review, we have discussed only two enzymes obtained
from the FBA, however, other results can be obtained and
consequently require further analysis. For instance, constraint-
based modeling has suggested that mitochondria-derived citrate
constitutes a fundamental metabolite that supports cell pro-
liferation. Thus, taking into account this information in the
computational model, the inhibition of ATP citrate lyase in the
cytoplasm prevents cancer cell proliferation and tumor growth
due to its role in lipid biosynthesis (Hatzivassiliou et al., 2005;
Hsu and Sabatini, 2008). Although a simple explanation of this
effect is that the inhibition of ATP citrate lyase has the final
effect of reducing the production of acetyl-coenzyme, a more
detailed analysis should be performed in the future that con-
siders the additional metabolic pathways that can contribute
to the formation of acetyl-coenzyme A, for instance, fatty acid
metabolism. Overall, these results provide evidence that FBA
is an appropriate formalism to simultaneously advance three
areas: (1) the integration of high-throughput data from cancer
studies, (2) the construction of a formal platform to develop
biological hypotheses, and (3) the design experiments to assess
the genotype–phenotype relationships identified using in silico
procedures.
In our opinion, this paradigm in systems biology—constraint-
based modeling—constitutes a cornerstone for the construction
of systemic models that will contribute to the understanding of
the metabolic activity in cancer cells. Undoubtedly, advances in
this understanding will be necessary to create a new paradigm
in biomedical sciences to elucidate the changes in normal cell
activity and improve the effectiveness of the clinical treatment of
human cancers.
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APPENDIX
The set of chemical reactions that comprises a network
can be represented as a set of equations including stoichio-
metric information. This information can be represented in
matrix form using the stoichiometric matrix, denoted by S.
This structure represents the key for the in silico analysis.
The stoichiometric matrix represents a linear transformation
between the flux vector (v) and the concentration vector (x).
dx
dt
= S · v
x =
⎛
⎜⎜⎜⎜⎜⎝
x1
x2
·
·
xm
⎞
⎟⎟⎟⎟⎟⎠
and v =
⎛
⎜⎜⎜⎜⎜⎝
v1
v2
·
·
vn
⎞
⎟⎟⎟⎟⎟⎠
FBA is a computational framework for analyzing and explor-
ing the phenotypic space of metabolic networks. FBA uses S,
and obeys mass conservation and the steady state assumption
(no variation in the concentration over time). For example, if
we identify the metabolic fluxes that maximize biomass produc-
tion when constrained by thermodynamics and mass balance
principles, we have:
max
[
biomass = ∑
i= 1
ci · Xi
]
such that∑
Si, j
·νj = 0 i = 1, 2 . . .m
−αj ≤ νj ≤ βj j = 1, 2 . . . n
where, Sij, are associated with the i-th metabolite in the j-th reac-
tion. Cellular growth (Xi) is related to a combination of essential
metabolites, whose contributions are weighted by the coefficients
ci. In addition, the parameters α and β provide information
about the limits of the enzyme capacities for each metabolic
reaction.
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